Reproduktiv salomatlik va uro-nefrologik tadqiqotlar jurnali 2022 № 1
Subject of the article
THE ROLE OF MYO-INOSITOL IN TREATING INFERTILITY AMONG PATIENTS WITH POLYCYSTIC OVARY SYNDROME (57-59)
Authors
Mamadjanova Shakhnoz Kahramonovna
Institution
Samarkand state medical institute
Abstract
Polycystic ovary syndrome (PCOS) is a highly prevalent disorder, representing the single most common endocrine-metabolic disorder in reproductive-aged women. PCOS is marked in 30 to 40% by insulin resistance and hyperandrogenism. Myo-inositol was noted to increase insulin sensitivity,decrease hyperandrogenism and improve the menstrual cycle.We conducted a research on the impact of Myo-inositol administration in PCOS and it marked a high effectiveness in normalizing ovarian function and maturing the oocyte and leading to pregnancy.
Key words
polycystic ovarian syndrome, myo-inositol, insulin sensitivity,hyperandrogenism, dysmenorrhea
Literature
1. Merviel P, Bouée S, Ménard M, Le Martelot MT, Roche S, Lelièvre C, et al. Which ovarian stimulation to which women: the polycystic ovary syndrome (PCOS). Gynecol Obstet Fertil Senol. 2017;45:623–31. 2. Chiu TTY, Rogers MS, Law ELK, Britton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF : relationship with oocyte quality. Hum Reprod. 2002;17:1591–6. 3. Lagana AS, Garzon S, Casarin J, Franchi M, Ghazzi F. Inositol in polycystic ovary syndrome: restoring fertility through a pathophysiologybased approach. Trends Endocrinol Metab. 2018;29:768–80. 4. Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double-blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11:347–54